RxDoctor Payments Data

Marcus Sims, MD

Cardiovascular Disease · Lawrenceville, GANPI 1427199546

Payments from drug & device makers

$31,691in general payments, 2019–2025

Across 410 payments — averaging $77.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$22K
  • Boston Scientific$825
  • AstraZeneca$660
  • Abiomed$625
  • Medtronic$609
  • Edwards Lifesciences$523
  • plus $6K from 37 others

What the payments were for

  • Speaking & faculty fees$19,50062%
  • Travel & lodging$720%
  • Food & beverage$12,02438%
  • Education$950%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,691 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$168,519
Medicare patients
901
Services billed
2,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$267,457
EntrestoSacubitril/Valsartan93$134,354
XareltoRivaroxaban83$85,661
JardianceEmpagliflozin64$81,563
BrilintaTicagrelor74$58,055
Repatha SureclickEvolocumab29$29,029
FarxigaDapagliflozin Propanediol33$25,882
Praluent PenAlirocumab12$17,941
Ranolazine ErRanolazine131$14,290
Droxidopa12$7,860
Metoprolol Succinate381$4,215
Isosorbide Dinitrate16$4,181
Atorvastatin Calcium399$3,121
Rosuvastatin Calcium181$2,319
Nebivolol Hcl39$2,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$486$267,457254 claims
NovartisEntresto$341$134,35493 claims
Johnson & JohnsonXarelto$507$85,66183 claims
AstraZenecaBrilinta, Farxiga$660$83,937107 claims
Boehringer IngelheimJardiance$331$81,56364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →